Current drug targets. Inflammation and allergy最新文献_第8页

Amyloidosis and auto-inflammatory syndromes. 淀粉样变和自身炎症综合征。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622786

Gilles Grateau, Isabelle Jéru, Saad Rouaghe, Cécile Cazeneuve, Nathalie Ravet, Philippe Duquesnoy, Laurence Cuisset, Catherine Dodé, Marc Delpech, Serge Amselem

{"title":"Amyloidosis and auto-inflammatory syndromes.","authors":"Gilles Grateau, Isabelle Jéru, Saad Rouaghe, Cécile Cazeneuve, Nathalie Ravet, Philippe Duquesnoy, Laurence Cuisset, Catherine Dodé, Marc Delpech, Serge Amselem","doi":"10.2174/1568010053622786","DOIUrl":"https://doi.org/10.2174/1568010053622786","url":null,"abstract":"Amyloidosis remains currently a severe potential complication of many chronic inflammatory disorders. It is not exactly know why some patients develop a progressive amyloidosis, whereas others do not although latent deposits may be present. A permanent acute phase response, ideally evaluated with serial measurement of serum protein SAA, the precursor of the AA protein deposited in tissues, seems to be a prerequisite to the development of inflammatory (AA) amyloidosis. Genetic factors have however been recently emphasized. Among persistent or emerging causes of AA amyloidosis, hereditary periodic fever syndromes also known as auto-inflammatory syndromes are a group of diseases characterised by intermittent bouts of clinical inflammation with focal organ involvement mainly: abdomen, musculoskeletal system and skin. The most frequent is familial Mediterranean fever which affects patients of Mediterranean descent all over the world. Three other types have been recently clinically as well as genetically characterised. A thorough diagnosis is warranted, as clinical and therapeutic management is specific for each of these diseases.","PeriodicalId":86954,"journal":{"name":"Current drug targets. Inflammation and allergy","volume":"4 1","pages":"57-65"},"PeriodicalIF":0.0,"publicationDate":"2005-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568010053622786","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24966460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 28

Molecular study of FMF patients in Armenia. 亚美尼亚FMF患者的分子研究。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622885

T Sarkisian, H Ajrapetyan, G Shahsuvaryan

引用次数: 43

The role of infections in the pathogenesis of autoimmune diseases. 感染在自身免疫性疾病发病机制中的作用。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622821

Michael Samarkos, George Vaiopoulos

{"title":"The role of infections in the pathogenesis of autoimmune diseases.","authors":"Michael Samarkos, George Vaiopoulos","doi":"10.2174/1568010053622821","DOIUrl":"https://doi.org/10.2174/1568010053622821","url":null,"abstract":"The autoimmune diseases result from inappropriate responses of the immune system to self antigens. The etiology of autoimmune diseases remains largely unknown but candidate etiologic factors include genetic abnormalities and infections. Although there are considerable data supporting the role of infections in a variety of autoimmune diseases, this role has been unequivocally established in only a few autoimmune diseases. The difficulty in establishing the infectious etiology of autoimmune diseases stems from several factors such as the heterogeneity of clinical manifestations in individual autoimmune diseases and the time interval between infection and autoimmune disease. The data on this association derive from clinical observations, epidemiological studies and research using laboratory techniques, protein sequence database screening and animal models. Infectious agents can cause autoimmune diseases by different mechanisms, which fall into two categories: antigen specific in which pathogen products or elements have a central role e.g. superantigens or epitope (molecular) mimicry, and antigen non-specific in which the pathogen provides the appropriate inflammatory setting for \"bystander activation\". The most important mechanisms are molecular mimicry and superantigens. As far as molecular mimicry is concerned the recent data on the degeneracy of T cell recognition shifted the focus from searching for linear sequence homology to looking for similarity of antigenic surfaces. Special mention has to be made to retroviruses as they have some unique means of inducing autoimmunity.","PeriodicalId":86954,"journal":{"name":"Current drug targets. Inflammation and allergy","volume":"4 1","pages":"99-103"},"PeriodicalIF":0.0,"publicationDate":"2005-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568010053622821","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24966464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 60

Behçet's disease as an autoinflammatory disorder. behaperet病是一种自身炎症性疾病。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622894

Ahmet Gül

引用次数: 219

MEFV mutation carriers and diseases other than familial Mediterranean fever: proved and non-proved associations; putative biological advantage. MEFV突变携带者和家族性地中海热以外的疾病:已证实和未证实的关联;假定的生物学优势。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622948

Daniel Cattan

引用次数: 53

Role of inflammatory mediators in angiogenesis. 炎症介质在血管生成中的作用。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622830

Antonella Naldini, Fabio Carraro

{"title":"Role of inflammatory mediators in angiogenesis.","authors":"Antonella Naldini, Fabio Carraro","doi":"10.2174/1568010053622830","DOIUrl":"https://doi.org/10.2174/1568010053622830","url":null,"abstract":"The angiogenic process involves several cell types and mediators, which interact to establish a specific microenvironment suitable for the formation of new capillaries from pre-existing vessels. Angiogenesis occurs in several physiological and pathological conditions, such as embryo development and wound healing, diabetic retinopathy and tumours. Inflammatory cells, namely monocytes/macrophages, T lymphocytes and neutrophils, fully participate in the angiogenic process by secreting cytokines that may affect endothelial cell (EC) functions, including EC proliferation, migration and activation. Angiogenesis is the result of a net balance between the activities exerted by positive and negative regulators. With regards to inflammatory cells and endothelium cross-talk, such balance is conceptually very similar to that of pro-inflammatory and anti-inflammatory mediators that modulate an appropriate inflammatory response. In this review we will mainly discuss the relevance of both physiological and pathological inflammatory processes in angiogenesis, with particular regards to microenvironmental contribution. We will also describe some of the most relevant pro-inflammatory cytokines in the modulation of the angiogenic process. Furthermore, we will concentrate on what has been recently reported about the mechanism by which some of these cytokines are induced during inflammation to promote a suitable microenvironment for angiogenesis and tumour progression. Pro-angiogenic cytokines, such as IL-1 and TNF, and anti-angiogenic cytokines such as IFN-gamma and IL-12, will be briefly described. We will try to provide a rationale for the use of both cytokines and cytokine blockades as novel potential pharmaceutical targets to modulate angiogenesis in chronic inflammation as well as in cancer.","PeriodicalId":86954,"journal":{"name":"Current drug targets. Inflammation and allergy","volume":"4 1","pages":"3-8"},"PeriodicalIF":0.0,"publicationDate":"2005-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568010053622830","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24965963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 277

CXC chemokines in angiogenesis relevant to chronic fibroproliferation. 血管生成中与慢性纤维增生相关的CXC趋化因子。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622902

Robert M Strieter, John A Belperio, Marie D Burdick, Michael P Keane

{"title":"CXC chemokines in angiogenesis relevant to chronic fibroproliferation.","authors":"Robert M Strieter, John A Belperio, Marie D Burdick, Michael P Keane","doi":"10.2174/1568010053622902","DOIUrl":"https://doi.org/10.2174/1568010053622902","url":null,"abstract":"The CXC chemokines are an unique family of cytokines known for their ability to behave in a disparate manner in the regulation of angiogenesis. The mechanisms for the different activity in regulating angiogenesis by members of this chemokine family is related to the following: 1) the presence or absence of the structural/functional motif (Glutamic acid-Leucine-Arginine; 'ELR' motif) that immediately precedes the first cysteine amino acid residue in the primary structure of these cytokines; 2) interferon-inducible gene expression; and 3) receptors that these chemokines use to mediate their biological activity. Members that contain the 'ELR' motif (ELR(+)) are potent promoters of angiogenesis, and mediate their angiogenic activity via binding and activating CXCR2 on endothelium. In contrast, members that are inducible by interferons and lack the ELR motif (ELR(-)) are potent inhibitors of angiogenesis, and bind to the alternatively splice variant of CXCR3, CXCR3B on endothelium. This review will discuss the biology of these angiogenic and angiostatic CXC chemokines, and discuss their disparate angiogenic activity in the context of a variety of chronic fibroproliferative disorders.","PeriodicalId":86954,"journal":{"name":"Current drug targets. Inflammation and allergy","volume":"4 1","pages":"23-6"},"PeriodicalIF":0.0,"publicationDate":"2005-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568010053622902","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24965966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 38

Familial Mediterranean fever in the post-genomic era: how an ancient disease is providing new insights into inflammatory pathways. 后基因组时代的家族性地中海热:一种古老的疾病如何为炎症途径提供新的见解。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622803

Philip E Schaner, Deborah L Gumucio

{"title":"Familial Mediterranean fever in the post-genomic era: how an ancient disease is providing new insights into inflammatory pathways.","authors":"Philip E Schaner, Deborah L Gumucio","doi":"10.2174/1568010053622803","DOIUrl":"https://doi.org/10.2174/1568010053622803","url":null,"abstract":"Familial Mediterranean fever (FMF, MIM24900), described as a clinical entity only slightly over a half-century ago, has ancient roots among populations surrounding the Mediterranean basin. It is the most prevalent of the hereditary periodic fever syndromes, a group of disorders characterized by episodic attacks of fever and inflammation. Seven years ago, it was discovered that FMF is caused by mutations in MEFV, a gene that encodes a protein variously called pyrin or marenostrin. As exciting as that discovery was, physicians and patients alike were disappointed that the protein sequence of pyrin/marenostrin did not immediately suggest clues as to the molecular etiology of FMF. Though we are still far from a complete understanding of the function of pyrin/marenostrin at the cellular level, continued study of this intriguing protein is revealing new molecular details about inflammatory processes; the emerging information is relevant not only to FMF, but to innate immunity in general. Data from several laboratories demonstrate that pyrin/marenostrin is intimately connected to three important cellular pathways: apoptosis, cytoskeletal signaling and cytokine secretion. These connections occur, at least in part, through the direct interaction of the pyrin/marenostrin protein with two cytosolic protein adaptors: ASC (also called PyCARD or Tms1) and PSTPIP (also called CD2BP1). Here, we review the more recent literature regarding the molecular and cellular biology of pyrin/marenostrin and pinpoint open questions for future study.","PeriodicalId":86954,"journal":{"name":"Current drug targets. Inflammation and allergy","volume":"4 1","pages":"67-76"},"PeriodicalIF":0.0,"publicationDate":"2005-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568010053622803","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24966461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 34

Complement: an inflammatory pathway fulfilling multiple roles at the interface of innate immunity and development. 补体:在先天免疫和发育的界面上发挥多重作用的炎症途径。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622993

D Mastellos, A E Germenis, J D Lambris

引用次数: 28

Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. 秋水仙碱或类似物治疗家族性地中海热的药理学和临床基础:最新进展。

Current drug targets. Inflammation and allergy Pub Date : 2005-02-01 DOI: 10.2174/1568010053622984

C Cerquaglia, M Diaco, G Nucera, M La Regina, M Montalto, R Manna

{"title":"Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update.","authors":"C Cerquaglia, M Diaco, G Nucera, M La Regina, M Montalto, R Manna","doi":"10.2174/1568010053622984","DOIUrl":"https://doi.org/10.2174/1568010053622984","url":null,"abstract":"Familial Mediterranean Fever (FMF), an autosomal recessive disorder, is characterised by recurrent attacks of fever and serositis, lasting 24-72 hours. Since 1972 colchicine has become the drug of choice for prophylaxis against FMF attacks and amyloidosis FMF-associated. Colchicine, an alkaloid neutral, is absorbed in the jejunum and ileum. It metabolised by liver and only small amounts are recovered unchanged in the urine. Really plasma half-life is prolonged in patients with liver or renal failure. Colchicine is able to prevent activation of neutrophils, binding beta-tubulin and making beta-tubulin-colchicine complexes; this way inhibits assembly of microtubules and mitotic spindle formation; moreover its mode of action includes modulation of chemokines, prostanoids production, inhibition of neutrophil and endothelial cell adhesion molecules. The minimal daily dose in adults is 1.0 mg/die, but in children there is not a definite dose. Since in vitro high dosages of colchicine stop mitosis, this drug might interfere with male and female fertility and with children growth, but, according to current guidelines and because of rare side effects of the drug, FMF patients are recommended to take colchicine. Since colchicine treatment is often complicated by frequent gastrointestinal side effects, by our experience, in order to improve colchicine tolerance we recommend: lactose-free diet and treatment of intestinal bacterial overgrowth and/or Hp-infection, assessed by breath tests. Since our data showed that 10-15% of FMF patients seem are non-responders or intolerant to colchicine, today we are working in the design of colchicine analogues which may have lesser toxicities and a larger therapeutic window.","PeriodicalId":86954,"journal":{"name":"Current drug targets. Inflammation and allergy","volume":"4 1","pages":"117-24"},"PeriodicalIF":0.0,"publicationDate":"2005-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1568010053622984","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"24966468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 174